Research programme: anti-PSGL-1 monoclonal antibody - Novartis

Drug Profile

Research programme: anti-PSGL-1 monoclonal antibody - Novartis

Alternative Names: Anti P-selectin glycoprotein ligand-1; Anti-PSGL-1-mAb - Novartis; SELK-2

Latest Information Update: 21 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Cytovance Biologics; Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma
  • No development reported Crohn's disease

Most Recent Events

  • 21 Nov 2016 Selexys Pharmaceuticals has been acquired and merged into Novartis
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in USA (Parenteral)
  • 06 May 2014 Preclinical trials in Multiple myeloma in USA (Parenteral) before May 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top